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Abstract The complement system is an enzyme cascade
that helps defend against infection. Many complement
proteins occur in serum as inactive enzyme precursors or
reside on cell surfaces. Complement components have
many biologic functions and their activation can eventually
damage the plasma membranes of cells and some bacteria.
Although a direct link between complement activation and
autoimmune diseases has not been found, there is
increasing evidence that complement activation signifi-
cantly contributes to the pathogenesis of a large number of
inflammatory diseases that may have autoimmune linkage.
The inhibition of complement may therefore be very
important in a variety of autoimmune diseases since their
activation may be detrimental to the individual involved.
However, a complete and long-term inhibition of comple-
ment may have some contra side effects such as increased
susceptibility to infection. The site of complement activa-
tion will, however, determine the type of inhibitor to be
used, its route of application and dosage level. Compared
with conventional drugs, complement inhibitors may be the
best option for treatment of autoimmune diseases. The
review takes a critical look at the relative merits of thera-
pies being developed to tackle inappropriate complement
activation that are likely to result in sporadic autoimmune
diseases or worsen already existing one. It covers the
complement system, general aspects of complement inhi-
bition therapy, therapeutic strategies and examples of
complement inhibitors. It concludes by highlighting on the
possibility that a better inhibitor of complement activation
when found will help provide a formidable treatment for
autoimmune diseases as well as preventing one.
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Introduction
The role of complement in human diseases, particularly
autoimmune diseases, was relatively unknown some time
ago, but with increasing evidence that complement acti-
vation significantly contributes to the pathogenesis of a
large number of inflammatory diseases, strategies that
interfere with its deleterious action have become a major
focus in pharmacological research [1, 2].
Attempts to efficiently inhibit complement include the
application of endogenous soluble complement inhibitors
(C1-inhibitor, recombinant soluble complement receptor
1-r sCR1), the administration of antibodies, either blocking
key proteins of the cascade reaction (e.g., C3, C5), neu-
tralizing the action of the complement-derived anaphyla-
toxin C5a, or interfering with complement receptor 3 (CR3,
CD18/11b)-mediated adhesion of inflammatory cells to the
vascular endothelium [3, 4].
In addition, incorporation of membrane-bound comple-
ment regulators (decay accelerating factor—DAF-CD55,
Membrane Cofactor Protein—MCP-CD46, CD59) has
become possible by transfection of the correspondent
cDNA into xenogeneic cells [5]. These complement inhi-
bitors target specific complement activators and prevent
them from initiating activation and if activation is under-
way, stop it from continuing [6, 7].
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Autoimmune disease
Autoimmune diseases remain a major health problem
despite enormous efforts to understand the underlying
causative mechanisms [8]. The lack of clarity with regard
to both the predisposing factors and the precise antigenic
targets of the immune response has restricted the devel-
opment of effective therapeutic approaches [9]. Autoim-
mune diseases are a result of loss of tolerance where an
organism fails to recognize its own constituent parts as
‘‘self’’ [1]. An essential prerequisite for the pathogenesis of
autoimmune diseases is indeed the breakage of immuno-
logical tolerance, leading to the immune system mounting
an effective and specific immune response against self
determinants [10, 11]. Several theories have been proposed
since the mid-twentieth century to explain the origin of the
exact genesis of immunological tolerance [10–12].
These include: coral deletion theory where self-reactive
lymphoid cells are destroyed during the development of the
immune system, Anergy theory where self-reactive T or
B-cells become inactivated in the normal individual and
cannot amplify the immune response, and Idiotype Net-
work theory, where a network of antibodies capable of
neutralizing self-reactive antibodies exists naturally within
the body [13–16]. There is genetic, sex, and environmental
factors associated with autoimmune diseases [16, 17].
Human leukocyte antigen (HLA) DR2, DR3, DR4 have
been shown to be strongly and positively correlated with
some autoimmune diseases and negatively correlate others
[17]. Sex also seems to have a major role in the develop-
ment of autoimmunity with most of the known autoim-
mune diseases tending to show a female preponderance
whilst in areas where multiple infectious diseases are
endemic, autoimmune diseases are quite rarely seen [18].
Certain chemical agents and drugs can also be associated
with the genesis of autoimmune conditions, or conditions
which simulate autoimmune diseases [19].
Autoimmune diseases can be broadly divided into sys-
temic and organ-specific or localized autoimmune disor-
ders, depending on the principal clinical pathologic
features of each disease [1, 8]. Systemic syndromes include
systemic lupus erythematosus (SLE), Sjogren’s syndrome,
Scleroderma, Rheumatoid Arthritis and polymyositis.
Local syndromes may be endocrinologic (insulin-depen-
dent diabetes mellitus—IDDM, Hashimoto’s thyroiditis,
Adddison’s disease etc.), haematologic (autoimmune hae-
molytic anaemia), neural (multiple sclerosis) or can
involve virtually any circumscribed mass of body tissue [1,
8, 11, 16].
The different autoimmune diseases can each affect the
body in different ways [1, 8]. For example, the autoimmune
reaction is directed against the brain in multiple sclerosis
and the gut in Crohn’s disease [20, 21]. In other
autoimmune diseases such as SLE (lupus), affected tissues
and organs may vary among individuals with the same
disease [16]. One person with lupus may have affected skin
and joints, whereas another may have affected skin, kidney
and lungs [16]. Ultimately, damage to certain tissues by the
immune system may be permanent as with destruction of
insulin-producing cells of the pancreas in Type 1 diabetes
mellitus [22].
Autoimmune diseases represent a class of diseases
which are often difficult to treat effectively [23]. Although
there are a number of drugs which exist to treat them, none
are adequate to control or inhibit the disease progression
[23, 24]. The inhibition of complement may be very
important in a variety of autoimmune diseases because as
the complement system becomes active, there may be
destruction and removal of cells and substances, which
may be detrimental to the individual [3]. It is useful,
therefore, to have substances which can be administered to
patients to prevent active complement activation thereby
preventing autoimmune diseases from occurring [3, 23,
25].
The complement system
The complement system is a complex system containing
more than 30 various glycoproteins present in serum in the
form of components, factors or other regulators and/or on
the surface of different cells in the form of receptors [26].
These are produced constitutively by macrophages and
hepatocytes, and are present in the circulation as inactive
molecules until they are cleaved by a protease, which in
turn converts them into a protease [17, 26]. Several com-
plement proteins are pro-enzymes and when activated
become the proteases that cut peptide bonds in other
complement proteins to activate them in turn [28]. Since
each activated protease can activate many substrate mole-
cules, the initial activation is rapidly amplified to produce
millions of effector molecules in the form of a cascade [26–
28].
There are actually three complement cascades [29].
They are activated by different molecules, but many of the
component proteins are the same and all the effector
functions are also the same [29]. The classical complement
cascade, activated by antigen-bound IgM and IgG, was
discovered first; the alternative complement cascade is
activated by bacteria cell surface molecules such as
lipopolysaccharide (LPS) from Gram negative outer
membranes, teichoic acid from Gram positive cell walls,
zymosan from fungal and yeast cell walls, and some par-
asite surface molecules; then the mannose-binding lectin
(MBL) cascade requiring synthesis of MBL by the liver in
response to inflammatory macrophage cytokines [30–32].
6 Page 2 of 15 Autoimmun Highlights (2016) 7:6
123
Complement activation stimulates several antimicrobial
activities [33]. The endpoint is the formation of a mem-
brane attack complex (MAC), which inserts into lipid
membranes of bacteria or eukaryotic cells and causes
osmotic lysis [34]. Also Complement fragments called
opsonins adhere to microorganisms and promote leukocyte
chemoattraction, antigen binding and phagocytosis, and
activation of macrophage and neutrophil killing mecha-
nisms [30, 31, 34].
Complement activation also leads to the generation of a
series of activation peptides that are capable of producing
inflammation [35]. In addition, complement is thought to
play a major role in the afferent limb of the immune
response, increasing the immunogenicity of antigens with
bound complement peptides [36]. It may also be important
in eliminating clones of lymphocytes involved in the
immune response to self antigens [37]. With the revelation
that complement plays a crucial role in the pathogenesis of
inflammatory tissue destruction, a great enthusiasm has
evolved for specific complement inhibition as a novel
treatment of human diseases [3, 5, 6, 38].
The complement system in relation
with autoimmunity
In autoimmunity, tolerance to self molecules (antigens) is
lost which results in the various autoimmune diseases. Loss
of tolerance to complement factors is one of the mecha-
nisms that results in an autoimmune disease such as atyp-
ical haemolytic uraemic syndrome (aHUS). aHUS is an
extremely rare, life-threatening, progressive disease that
frequently has a genetic component and in most cases
caused by chronic, uncontrolled activation of the comple-
ment system [39]. The disease affects both children and
adults and is characterized by systemic thrombotic
microangiopathy (TMA) that leads to the formation of
blood clots in small blood vessels throughout the body.
This can lead to stroke, heart attack, kidney failure, and
eventually death [39–41]. The complement system activa-
tion may be as a result of mutations in the complement
regulatory proteins (factor H, factor I, or membrane
cofactor protein) [41, 42], or is occasionally due to
acquired neutralizing autoantibody inhibitors of the com-
plement system components, for example anti-factor H
antibodies [43]. Subsequently, tolerance to complement is
lost in patients with aHUS and most of them demonstrate
the chronic, uncontrolled and excessive activation of
complement resulting from the production of the anti-fac-
tor H autoantibodies or genetic mutations in any of several
complement regulatory proteins (e.g., factor H, factor HR1
or HR3, membrane cofactor protein, factor I, factor B,
complement C3, and thrombomodulin) [44]. The end result
if this is platelet and white blood cell activation and
damage to endothelial cells, leading to systemic TMA,
which manifests as decreased platelet count, haemolysis,
damage to multiple organs, and then death [45–47].
Despite the use of supportive care, historically an estimated
33–40 % of patients die or develop end-stage renal disease
(ESRD) with the first clinical bout of aHUS [42].
General aspects of complement inhibition therapy
Complement inhibition in human disease
Several disease states such as immune complex and
autoimmune diseases and genetic deficiencies of some
complement regulators are associated with inappropriate
activation of complement [48]. In some diseases, comple-
ment is activated for a long or indefinite period while in
others for a comparatively short time; in some it is acti-
vated systemically, in others locally in tissue or organs; in
some the whole complement cascade is activated, in others
only a few components are activated [31, 33]. In some, the
classical pathway is activated whilst in others the alterna-
tive pathway [31, 33].
In many complement activating diseases, biological
activities of complement fragments become detrimental,
resulting in tissue injury and disease [48]. Inhibition of
complement by specific inhibitors is therefore likely to
arrest complement-mediated disease processes [3]. From
this point of view, some laboratories are developing low
molecular weight synthetic inhibitors, whereas others are
developing natural or recombinant forms of high molecular
weight inhibitors of complement present in plasma or on
cell surfaces with the eventual aim of manipulating com-
plement system in human diseases [49, 50].
The complement cascade
Complement activation involves three major steps or cas-
cades: activation of a C3 convertase to cut C3 into C3a and
C3b; activation of a C5 convertase to cut C5 into C5a and
C5b, and formation of a membrane attack complex (MAC)
[31–34]. These cascades are initiated through three path-
ways: Classical pathway (CP), Alternative pathway (AP)
and Lectin Pathway (LP) with all three pathways merging
through a common intersection complement C3 [31–34].
Alternative and classical complement cascades produce
different C3 and C5 convertases, but both produce the split
product of C3 and C5 and both form MAC as shown in
Fig. 1.
The potential site of complement’s therapeutic inhibition
The site of complement activation will determine the type
of inhibitor to be used, its route of application and site of
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inhibition [38]. Many of the procedures are based on the
blocking of complement activation at the C3 level which
implies a general and broad inhibition but others are based
on the selective blocking of C5 activation which leads to
the inhibition of C5a and C5b-9 formation [38]. Since
complement activation is detrimental with deadly conse-
quences, its inhibition should be or can be extended as
wide and completely covering all complement factors;
however, terminal blockage of the pathway allows C3
activation to offer effective defence mechanism for the
body [51, 52]. Clinical validation of the above arguments is
limited due to the fact that these arguments are oversim-
plified because complement activation mechanism and its
contribution to pathophysiology of different clinical con-
ditions are very diverse requiring differential approxima-
tion and several strategies pertaining to the inhibition
process [53]. One such strategy is targeting the initiation
step of the complement activation and blocking each of the
3 initial pathways separately [54]. The alternative pathway
activation can be inhibited by the inhibition of factor D (the
rate limiting step of the alternative pathway) [54].
Even though blocking AP as an initial step blocks
amplification of complement activation, CP and LP acti-
vation remains intact as C1q or MBL mediated opsonisa-
tion and receptor binding are not affected [54]. Also, AP
amplification loop may cause detrimental activation no
matter the initial trigger [54]. A second strategy involves
targeting specific activation products or their respective
receptors especially the anaphylatoxins (C3a or C5a) [55].
In certain conditions such as airway hyper-responsiveness,
there may be the need or indication of selective blocking of
C3a using anti-C3a antibodies or C3aR antagonists, which
preserves other important C3 functions [56–58]. In the
same way C5a function can be blocked in a condition
associated with systemic complement activation, leaving
C5b-9 pathway free for pathogenic defence [56–58].
Side effects
A complete and long-term inhibition of complement may
have some detrimental side effects, as suggested by
observations made in patients with various complement
deficiencies. Such patients have an increased susceptibility
to infection (mainly encapsulated bacteria including
meningococci and Neisseria), autoimmune and immune
complex diseases that arise from impaired opsonisation,
adaptive immune response, tolerance or elimination of
immune complex [59]. However, in many human diseases
only short-term inhibition would be needed, e.g., in
ischaemia reperfusion injury or in acute humoral rejection
in transplantation [60].
It is important to take a look at the level of complement
inhibition especially when considering long-term treatment
in chronic diseases as detrimental effects could be reduced
by a certain degree of inhibition and still leave defence
mechanisms intact [54]. For example, blocking C3 activity
leads to a higher risk of infection whilst the selectively
blocking of one of the three activation pathways may
reduce risk of infection [54, 57]. In addition, it is quite
possible that down-regulation rather than blockade of
complement may be sufficient on many occasions [61].
Thus, although we should be cautious with inhibiting
complement, it would be unwise not to start clinical
investigations because of potential side effects which may
be prevented (e.g., immunization against meningococcal)
or for which a close surveillance can be proposed.
Therapeutic strategies
Mode of administration, clearance and long-term
treatment
The dosage level and mode of administration of any
complement inhibitor depend on the nature of the inhibitor,
the nature of the condition to be treated, and the history of
the individual patient [38, 62]. Patients suffering from
chronic diseases and requiring long-term treatment must
have a proper route of administration where it is supposed
that oral, nasal or rectal administration are better than
intravenous injection [38, 62]. Local application is rec-
ommended for organ-specific diseases such as glomeru-
lonephritis [38]. Systemic administration of inhibitors
which may be by injection or by transmucosal or trans-
dermal delivery is generally required for systemic diseases
Fig. 1 The complement cascade leading to formation of mark attack
complex (MAC) and other alternate effects of complement activation
(inflammation and clearance)
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such as sepsis [38]. Administration by injection may be
intravenous, intramuscular, intraperitoneal or subcutaneous
[63]. Inhibitors such as recombinant proteins and small
molecular inhibitors that have short half-life are best used
for the treatment of acute conditions [38]. On the other
hand, when they are combined with human immunoglob-
ulins, they acquire increased half-lives [38, 62].
The inhibitors are sometimes made into pharmaceutical
compositions (formulations) comprising the inhibitor and a
pharmaceutically acceptable carrier [38]. Formulations for
injection are generally biocompatible solutions of the
active ingredient, such as Hank’s solution or saline [38,
63]. Formulations for transdermal or transmucosal admin-
istration generally include penetrants such as fusidic acid
or bile salts in combination with detergents or surface-
active agents [64]. The formulations can then be manu-
factured as aerosols, suppositories or patches which give
the inhibitors a longer half-life and subsequently longer
clearance [4, 65]. Autoimmune diseases are often chronic,
requiring lifelong care and monitoring, even when the
person may look or feel well [8, 10]. Currently, few
autoimmune diseases can be cured or made to ‘‘disappear’’
with treatment [9]. However, many people with these dis-
eases can live normal lives when they receive appropriate
medical care in a long-term treatment [11].
Targeted application
The main aim of targeted application of complement
inhibitors is to reduce any potential side effects whilst
trying to treat a condition [66]. This is the best way of
treatment if the disease process is clearly organ specific
[57]. There can be specific and non-specific targeting
where inhibitors are directed at certain organs or cells in
the case of specific and any membrane in the case of non-
specific [67]. In non-specific targeting, an approach such as
membrane ‘‘tagging’’ is employed. Membrane tagging is
achieved by coupling an inhibitor to a lipid tail and this tail
binds to the affected membranes [25, 68]. In situations
where tagged forms of inhibitors have been used in
experiments, they have proved more potent as compared to
the parent molecules, highlighting the importance of this
approach. sCR1, sCD59 and the rodent complement C3-
inhibitor Crry have all been tagged with promising results
in experiments [4, 67, 68].
Targeted applications have also been achieved by the
use of antigen-specificity of antibody-conjugates [68]. In
this approach, DAF and IgG antibody were successfully
conjugated and targeted to the specific antigen whose
antibodies were used. Antigen-targeted forms of sCD59
and CR2 have been produced which bound to C3 opsonised
cells and showed a higher or greater potency than when the
conjugates were used individually [67]. Another targeting
approach is the conjugation of the inhibitor to an inflam-
mation modulating molecule [67, 68]. One such conjugate
is sCR1-sL(x) which combines complement inhibition with
leukocyte recruitment and adhesion as the sL(x) is a ligand
for E and P selectins which facilitates the leukocyte
adhesion [69]. This combination was found to be highly
potent in comparison with the sCR1 by itself [69].
Gene therapy
This is where a ‘‘normal’’ gene is inserted into the genome
to replace an ‘‘abnormal’’ disease causing gene. A carrier
molecule called a vector must be used to deliver the ther-
apeutic gene to the patient’s target cells [70]. Currently, the
most common vector is a virus that has been genetically
altered to carry normal human DNA [70, 71]. A gene
therapy approach using retrovirally transduced soluble
complement receptor 1 (CD35), an inhibitor of the classical
and alternative pathway of complement activation in DBA/
1 mice, has been shown to have a beneficial effect,
reducing inflammation and the development of collagen-
induced arthritis (CIA) in these mice [71].
Complement inhibitors
The proteins which inhibit complement activation in fluid
phase limit the generation of complement fragments such
as C4b and C3b [72]. They also render these fragments
inactive thereby reducing the extent of cellular damage to
self cells. These fluid phase proteins include C1-inhibitor
(C1-INH), C4-binding protein (C4BP), factor H, and factor
I [72]. In addition, two fluid phase proteins, clusterin and
vitronectin inhibit the formation of cytolytic MAC [51].
These inhibitors are regulators of the complement system
and keep the system under control by inhibiting its acti-
vation except properdin that stabilises alternative C3 con-
vertase [51, 72].
C4b and C3b fragments may escape inactivation by fluid
phase inhibitors of complement activation and can get fixed
to self cells [73]. These fragments are inactivated by cell
membrane embedded regulators of complement such as
DAF, MCP and CR1 [72, 73]. If the activation of com-
plement is extensive, in spite of the action of DAF, MCP
and CR1, a significant extent of C3/C5 convertases may be
formed on self cell which can sequentially generate MAC
which could cause cell lysis [72, 73].
Two cell membrane proteins, CD59 and homologous
restriction factor (HRF), render MAC non-cytolytic while
it is being formed on the self cell [74]. Non-cytolytic MAC
can activate self cell but cannot lyse it [74]. Thus, cell
surface regulators of formation of C3/C5-convertases and
MAC protect self cell from lysis [68]. Fluid phase
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inhibitors in conjunction with membrane embedded inhi-
bitors protect cells from autologous complement [68]. It is
important to note that most of the drugs that qualifies as
candidates for therapeutic complement inhibition are either
naturally occurring complement inhibitory proteins or their
derivatives [68, 74].
C1-inihibitor
C1-inhibitor (CI-INH) is a serine protease inhibitor protein
(serpin) that is naturally occurring [72]. It is the largest
member of the serpin class of proteins (G1) and probably
the highest glycosylated [72]. It has an O-glycosylated
residue which is uncommon for proteins that are not
membrane-bound and inhibits Clr and C1s as well as
controlling mannose-binding protein-associated serine
protease (MASP)-1 and MASP-2 of the lectin pathway
[75].
The gene for human C1-inhibitor is located on the ele-
venth chromosome (11q11-q13.1) and is produced mainly
in the liver, but also by activated monocytes and other cell
types [72]. It circulates in blood at levels of around
0.25–0.45 g/l and is the major inhibitor of both the early
activation steps of classical pathway and contact activation
of the complement system [51, 54]. Deficiency of this
protein is associated with hereditary angioedema which is
the swelling of the blood vessels [76].
Patients of hereditary angioedema have defects in one of
the two genes responsible for formation of CI-INH [76].
These patients have one half to one-third the normal level
of CI-INH and have frequent attacks of angioedema which
may arise from activation of the kinin generating system or
from activation of the complement system with generation
of peptides that cause vascular leakage [76].
Advantages
C1-esterase inhibitor (C1-INH) concentrate prepared from
human plasma is being successfully used for the treatment
of hereditary angioneurotic oedema. Recently, C1-INH has
been found to be consumed in severe inflammation and has
been shown to exert beneficial effects in several inflam-
matory conditions such as human sepsis, postoperative
myocardial dysfunction due to reperfusion injury, severe
capillary leakage syndrome after bone marrow transplan-
tation, reperfusion injury after lung transplantation, burn,
and cytotoxicity caused by IL-2 therapy in cancer [51, 76].
C1-INH also regulates the activation of kallikrein,
plasmin in the fibrinolytic pathway, the activation of factor
XI in the coagulation cascade and activated factor XIIa
[77]. In the presence of C1-INH deficiency, the classical
complement pathway can be inappropriately or excessively
activated [78]. Immune complexes trigger the activation of
the first component C1 to C1 esterase and C1 esterase then
acts with its natural substrates C4 and C2 to form the
complex C4b2b [77]. Formation of this new complex (and
associated C3 activation) leads to the production of ana-
phylactic, chemotactic and vasoactive peptides (C2a, C3a,
C5a) [78].
C1-INH protein blocks both the spontaneous activation
of C1 and the formation of activated C1, therefore not
allowing the C2, 4 complex to be created [71, 72]. In the
kinin releasing system, C1 INH regulates conversion of
prekallikrein to kallikrein [72]. C1-INH deficiency results
in an increase in kallikrein, which in turn increases bra-
dykinin production [77]. Long-term prophylaxis with C1-
INH may be necessary in patients where tranexamic acid or
steroids are not effective, not tolerated or contraindicated
[71]. This may include those with underlying throm-
boembolic disease or during pregnancy [75, 77].
Disadvantages
C1-inhibitor has been widely used in a number of clinical
conditions and when used for therapeutic treatment, it is
not necessary complement dependent, but may well be
explained by inhibition of other proteins [79]. C1-inhibitor
deficiency is the bases on which treatment is offered as
controlled studies are not available [79]. Inhibitory effects
of C1-INH on factor XIIa, factor XIa and plasmin have also
been described with the end result of increased vascular
permeability and massive local uncontrolled oedema [77,
79]. This implies that CI-INH is not only complement
related but other substances as well [72].
Recombinant proteins
These include the use of pharmacological agents such as
soluble recombinant human CR1, CR2, MCP, DAF, C4BP
and factor H [80]. All the complement regulatory proteins
are candidates when extensive inhibition of complement is
required [49, 50]. This is because they all interfere with the
activity of C3 and C5 convertases except CR2 which may
play a minor role [49, 50].
Compared with conventional drugs, recombinant pro-
teins for therapy remain attractive to date, for reasons
having to do with both the biological properties of proteins
and the economics of drug development [81]. The time
required to develop protein drugs is shorter than that for
conventional drugs and, although a therapeutic protein has
a 40 % probability of becoming a marketable drug, this
figure is approximately 10 % for a new chemical entity,
partly because of the lower toxicity of proteins compared
with chemical compounds [4, 81]. The use of recombinant
proteins, however, has its advantages as well as disad-
vantages [4].
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Soluble CR1
Several recombinant variants of complement receptor 1
(CR1) have been produced with the most effective of these
appearing to be sCR1-SLe x [68]. The sCR1 part of this
recombinant inhibits complement and the carbohydrate
SLe x moiety inhibits selectin mediated interactions of
neutrophils and lymphocytes with endothelium [68].
Although clinical trials of sCR1 in humans are eagerly
awaited, several of the recombinant versions of sCR1 have
been shown to suppress ischaemia reperfusion injury,
thermal trauma and immune complex mediated inflam-
mation [68].
Advantages of soluble CR1 CR1 has cofactor and decay
accelerating activity in both classical and alternate path-
ways [67]. Deletion of the transmembrane part of the
molecule leads to the production of the soluble form-sCR1
which is potent in their inhibitory activity at concentrations
equivalent to 1 % of physiological C4BP and factor H [67].
When combined with an albumin binding receptor, sCR1
attains a longer half-life with improved targeting [67].
There has been a lot of use of sCR1 in a number of
animal disease models that has given a lot of promising
results with prevention in the following conditions; liver
injury, local and remote lung injury in skeletal muscle,
local and remote injury in rat intestine and gut ischaemia
and endothelial cell function after haemorrhage and
resuscitation in rats [82]. sCR1 has been shown to prevent
tissue damage in experimental myocardial infarction [82].
A lot more benefits of sCR1 have been recorded with
regard to autoimmune diseases including, immune-com-
plex and complement-mediated lung injuries and thermal
trauma in rats, passive reverse Arthus reaction and dermal
immune complex mediated vasculitis in experimental
arthritis in rats [53]. In experimental glomerulonephritis,
myasthenia gravis as well as allergic encephalomyelitis,
sCR1 has proved to be efficient in treatment [52].
sCR1 has been shown experimentally to be effective in
reducing hyperacute rejection in xenotransplantation
highlighting the role of complement in graft rejection [83].
Even in allotransplant, sCR1 showed beneficial effects.
With development of sCR1 into a pharmaceutical prepa-
ration which has been tested in patients with acute
myocardial infarction, lung transplantation and post-car-
diopulmonary bypass syndrome, results of efficient com-
plement inhibition have been shown [70]. In patients with
factor H deficiency, soluble recombinant CR1 may block
immediately the excessive activation of complement and
restore C3 levels [84].
Disadvantages of soluble CR1 On its own, sCR1 has a
short half-life and only acquires a longer and sustainable
half-life when it is recombined with other substances [83].
It lacks a proper targeting on its own and if not properly
administered, will not give a good end result [83].
C4BP, factor H and factor I
C4BP and factor I are responsible for regulation of C4b.
C4BP binds to C4b and facilitates its cleavage by the
proteolytic enzyme factor I [85]. Factor H acts as an
obligate cofactor in the fluid phase and as an accelerator of
C3 cleavage on cell surfaces [84, 85].
Advantages of C4BP, factor H and factor I Factor H,
Factor I and C4-binding protein (C4BP) are soluble com-
plement inhibitors that are likely to be effective membranes
in complement-mediated diseases if they inhibit activation
of complement before or at the stage of formation of C3/C5
convertase [71]. C4BP has been shown to inhibit the
classical pathway whilst Factor H inhibits the alternate
pathway [85]. This inhibition suppresses damage of self
cells and C5a-induced recruitment of neutrophils and
inflammation.
Besides the potential uses of fluid phase regulators in
substitution therapy, a novel use of C4BP came into light
when it was shown that human complement on swine
endothelial cells was inhibited by a surface bound form of
C4BP-GPI (consisting of short consensus repeats 1–8
(SCRs1–8) of a-chain of C4BP and a glycosyl-phos-
phatidyl-inositol (GPI) moiety of DAF [86]. Surface-in-
duced complement activation was abrogated by the binding
of Factor H to artificial surface which also improved bio-
compatibility [67].
Several patients who suffer from factor I deficiency have
been diagnosed [87]. In this deficiency, regulation of C3/
C5-convertase of the alternative pathway is impaired [87,
88]. These patients have very low plasma levels of native
C3 and factor B [87]. The underlying basis for this low
plasma level of C3 and factor B seems to be the increased
generation of C3bBb complex whose decay is reduced due
to factor I deficiency [88]. Circulating C3bBb generates
high levels of C3b which in turn leads to the generation of
more C3bBb complex [87, 88]. Free C3b or C3b in this
complex is not converted to C3bi or C3d. Administration of
factor I to one of the patients with factor I deficiency
normalized C3b levels within few minutes [87, 88]. Factor
I, Factor H and C4BP are likely to be effective in substi-
tution therapy in patients with their deficiencies [87, 88].
Factor I has been used in the treatment of factor I defi-
ciency [87, 88].
Disadvantages of C4BP, factor H and factor I Factor H
and C4BP are far much less potent than recombinant sol-
uble CR1 in inhibiting classical and alternative pathways
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[75]. Thus, they have not been used in the treatment of
complement-mediated diseases. Although recombinant
factor H has been produced, neither natural nor recombi-
nant factor H has been tried in factor H deficiency. C4BP
has also not yet been tried in the replacement therapy in
C4BP deficiency [84, 85].
Soluble DAF
Decay accelerating factor (DAF) (CD55) is a single-chain
membrane protein that is a potent accelerator of C3 and C5
convertase decay [89]. It has no factor I cofactor activity
and acts to limit membrane damage if complement is
activated on a host cell surface [89].
Advantages of soluble DAF DAF is composed of four
short consensus repeats (SCRs) plus a serine/threonine-
enriched domain that is capable of extensive O-linked
glycosylation [90]. DAF is attached to cell membranes by a
GPI anchor and through its ability to bind C4b and C3b; it
acts by dissociating the C3 and C5 convertases in both the
classical and alternative pathways [90]. Soluble versions of
DAF (sDAF) have been shown to inhibit complement
activation in vitro as well as in the reversed passive Arthus
reaction in guinea pigs [53].
Disadvantages of soluble DAF Unlike CR1, which pos-
sesses both extrinsic and intrinsic activity, DAF functions
only intrinsically by inactivating convertases assembled on
the same cell membrane on which it is expressed and not
those convertases formed on external membranes [90].
Soluble MCP
With Membrane cofactor protein (MCP), a limited number
of studies have so far been carried out with regard to
recombinant sMCP’s ability to inhibit complement in vitro
and in vivo and with organs of animals transgenic for
hMCP in the field of xenotransplantation [70].
Advantages of soluble MCP sMCP has been shown to
prevent reverse passive Arthus reaction and prolonged
hyperacute xenograft rejection. Also, sMCP fused with a
soluble form of the low affinity human IgG receptor Fc
gamma RII proved to be more effective in protecting
xenograft rejection than sMCP on its own [64].
A combination of sDAF and sMCP that retains decay
acceleration and cofactor activity is more potent than each
protein on its own. This recombinant Chlorophyll a-b
binding protein 2 (CAB-2) has been able to offer protection
in the passive reverse Arthus reaction and in Forssman
shock [91].
Disadvantages of soluble MCP There has been limited
number of studies carried out regarding soluble MCP and
therefore its ability as therapy cannot be emphasised [38].
Soluble MCP is not as potent on its own as when it is
combined with other substances [38].
Soluble CD59
Advantages of soluble CD59 CD59 is yet another regu-
latory protein that prevents assembly of the complete C5b-
9 complex on target cells and so prevents complement-
mediated lysis. In certain forms of glomerulonephritis,
arthritis and encephalomyelitis selective C5b-9 may be
indicated which will require the use of CD59 [68].
Disadvantages of soluble CD59 A soluble form of CD59
which is inefficient in the fluid phase has been constructed.
It is being fused with sDAF with the hope of creating a
recombinant that has a C5b-9 and C3/C5 inhibitory activity
but its therapeutic effect has not been shown [92].
Using antibodies
It has been reported that intravenous immunoglobulin
blocks the binding of C3 to target tissues [38]. Subse-
quently, it was reported that not only is C3 binding to target
tissues blocked by high levels of monomeric
immunoglobulin, but C4 binding to target tissues is
blocked as well [38]. There are data that suggest that since
C4 must be activated and must bind to a target before C3, it
is the blocking of C4 binding that is central to classical
pathway inhibition [55]. Further research has now shown
that this blockade is due to activity of the Fc fragment of
the IgG [55]. There is the combined advantage of speci-
ficity and long half-life with the use of monoclonal anti-
bodies, the only problem being the mode of administration
which is parenteral.
Anti-MBL, anti-factor D and anti-properdin
The lectin pathway is the third pathway through which
complement is activated and is shown to have importance
in pathogenesis of ischaemia–reperfusion injury [31]. An
anti-MBL antibody against the lectin pathway has been
developed and has been shown experimentally to improve
survival in septicaemia [75].
Anti-factor D against factor D, the rate limiting step in
the alternative pathway has been developed and has been
tested in baboons undergoing Cardiopulmonary bypass
(CPB) where they were found to inhibit complement and
leukocyte activation [93]. Properdin binds to C3 convertase
(C3bBb) and stabilises it, thus slowing its decay and
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allowing it to continue the complement cascade. Anti-
properdin therefore prevents the continuation of the com-
plement cascade [93].
Anti-C5
Inhibition of C5 activation using high-affinity anti-C5
monoclonal antibodies presents another therapeutic
approach for blocking complement activation [88]. This
strategy is aimed at inhibiting the formation of C5a and
C5b-9 via both the classical and alternative pathways,
without affecting the generation of C3b, a C3 opsonic
product that is critical for antibacterial defences [88].
Another suggested advantage of using monoclonal
antibodies to block C5 activation is the prevention of the
direct cleavage and activation of C5 by oxygen radicals or
by enzymes released from injured tissues during inflam-
mation [89]. There are no natural inhibitors for activated
C5 and they can be activated independent of C3, bringing
forth the need to develop specific inhibitors.
Anti-C5 antibody has been used experimentally to treat
collagen-induced arthritis which prevented the disease
from the onset and also treated existing disease [88]. In
experimental myocardial infarction, anti-rat C5 mono-
clonal antibody was found to be protective, also in an
artificial cardiopulmonary bypass model, there was
demonstration of terminal pathway activation inhibition
[94]. Hyperacute graft rejection in a model was also pre-
vented [94].
Some anti-C5 antibodies such as the humanized single
fragment (h5D1.1-scFv) have actually reached clinical
trials called pexelizumab with a focus on targeting com-
plement in cardiovascular disease. Pexelizumab trials have
shown a lot of benefits including complement inhibition
with subsequent reduced leukocyte activation and postop-
erative complications in patients undergoing CPB; patients
with isolated coronary artery bypass grafting; and reduc-
tion in death and myocardial infarction [94]. C-reactive
protein (CRP) and IL-6, which are both mediators corre-
lating to mortality, were shown to be significantly reduced
in patients treated with Pexelizumab.
Anti-C5a
As the most biologically potent fragment formed from C5
during complement activation, C5a is a good target for
inhibition when looking to prevent complement activation.
There has recently been an approach using monoclonal
antibodies that react with C5a without inhibiting the
cleavage of C5 [95]. In this approach, C5a is pre-neutral-
ized before its formation and thereby have the efficacy of
C5a neutralization increased. This has been investigated
with human whole blood of Neisseria infection where there
was complete inhibition of inflammatory reaction with no
effect on bacterial killing.
Anti-C5a antibodies have been shown to reduce
myocardial injury, reduced neutrophil-mediated impair-
ment of endothelium-dependent relaxation after CPB,
reduced local and remote injury in intestinal injury,
improved survival and reduced Il-6 production and oxygen
demand [94]. A possible role of C5a in activation of other
plasma cascade system was shown in a rat model when C5a
antibodies ameliorated impairment of the coagulation and
fibrinolytic system.
Anti-C5b-9
Prevention of formation of C5b-9 has been found to reduce
tissue damage in rat hearts perfused with human serum.
This was achieved with the use of anti-C8 which also
inhibited platelet activation during simulated CPB [89].
Small molecule inhibitors
Small molecule peptides and their derivatives are useful in
therapeutic and prophylactic contexts [96]. As complement
binding can account for substantial tissue damage in a wide
variety of autoimmune/immune complex mediated syn-
dromes such as systemic lupus erythematosus and vasculitis,
inhibition of the complement systembypeptides is likely to be
desirable therapeutic intervention in these cases [55]. Peptides
can also be used to inhibit complement activation, which is
desirable in cases that involve tissue damage brought about by
vascular injury such as myocardial infarction, cerebral vas-
cular accidents or acute shock lung syndrome [96].
C1 binding peptides
Peptide fragments of the Fc fragment of IgG that retain the
complement blocking activity of intact immunoglobulin, as
well as derivatives of such peptides that interact with C1q
have been produced [51]. They prolong xenograft survival
and it should be noted that C1q is activated by several
substances which may be of pathogenic importance but
only by antibodies [52].
Compstatin
Compstatin is a 13-residue cyclic peptide that was isolated
with the use of combinatorial peptide libraries to identify
C3 binding peptides. Compstatin blocks cleavage of C3
and highly specific for C3 binding [97]. In an in vitro
model of extra corporal circulation, compstatin was found
to reduce complement and granulocyte activation. Animal
studies of this peptide are limited because it works only in
primates.
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There have been a number of natural and synthetic
substances that have come out as having complement
inhibitory capability but may not be complement specific
[4]. They have a number of effects on complement and
several complement inhibitory proteins including C1-in-
hibitor [4]. Some of these substances include: high-dose
intravenous immunoglobulins (IVIG), Cobra venom factor
(CVF), nafamostat mesilate, aprotinin, K-76 monocar-
boxylic acid and heparin [38].
Eculizumab
Eculizumab which is formulated to soliris is a humanized
monoclonal antibody against complement protein C5 that
inhibits terminal complement activation [5]. It has been
shown to prevent complications of some autoimmune dis-
eases and improve quality of life and overall survival [98].
As stated, eculizumab is a recombinant humanized mono-
clonal IgG2/4j antibody produced by murine myeloma cell
culture and purified by standard bioprocess technology. It
contains human constant regions from human IgG2
sequences and human IgG4 sequences and murine com-
plementarity-determining regions grafted onto the human
framework light- and heavy-chain variable regions. Again,
eculizumab is composed of two 448 amino acid heavy
chains and two 214 amino acid light chains and has a
molecular weight of approximately 148 kDa [99]. It is
made into a sterile, clear, colourless, preservative-free
10 mg/mL solution for intravenous infusion and is supplied
in 30-mL single-use vials. It is formulated at pH 7 and each
vial contains 300 mg of eculizumab, 13.8 mg sodium
phosphate monobasic, 53.4 mg sodium phosphate dibasic,
263.1 mg sodium chloride, 6.6 mg polysorbate 80 (veg-
etable origin) and Water for Injection [100].
Eculizumab selectively targets and inhibits the terminal
portion of the complement cascade. It specifically binds to
the terminal Complement component 5, or C5, which acts
at a late stage in the complement cascade [2, 48]. When
activated, C5 is involved in activating host cells, thereby
attracting pro-inflammatory immune cells, while also
destroying cells by triggering pore formation [2]. By
inhibiting the complement cascade at this point, the nor-
mal, disease-preventing functions of proximal complement
system are largely preserved, while the properties of C5
that promote inflammation and cell destruction are impe-
ded [101]. Eculizumab therefore inhibits the cleavage
of C5 to C5a and C5b by the C5 convertase, which pre-
vents the generation of the terminal complement complex
C5b-9. Both C5a and C5b-9 cause the terminal comple-
ment-mediated events that are characteristic of paroxysmal
nocturnal hemoglobinuria (PNH) and atypical haemolytic
uraemic syndrome (aHUS) [101]. Eculizumab injection is
therefore used to treat PNH and aHUS [99, 102].
The metabolism of eculizumab is thought to occur
via lysosomal enzymes that cleave the antibody to gener-
ate small peptides and amino acids and the volume of
distribution of eculizumab in humans approximates that
of plasma [99].
Discussion
Activation of complement is an essential part of the
mechanism of pathogenesis of a large number of human
diseases [2]. Inhibition of complement activation by
pharmacological means is therefore likely to suppress or
prevent disease processes in complement-mediated dis-
eases [3]. It is for this reason that low molecular weight
synthetic inhibitors of complement are being developed
and high molecular weight natural inhibitors of human
origin present in plasma or embedded in cell membrane are
also being purified or produced in their recombinant forms
[49].
To develop effective and safe anti-complement thera-
peutics, however, the main issue or challenge is to balance
the beneficial effects that are obtained by the inhibition
with the preservation of sufficient functional activity for
antimicrobial protection and for tissue homoeostasis as
complement has other beneficial effects in combating
infection [30, 49]. There is much enthusiasm for such
therapies that will probably be disease specific so as to
prevent any possible associated side effects. Studies have
been performed and some are still ongoing in both rodents
and humans using different inhibitors and testing admin-
istration routes ito come out with the right therapy [38].
Most of the evidence for the role of complement in
preventing systemic damage comes from experimental data
obtained in these studies in which the addition of com-
plement inhibitors blocks or reduces damage [49]. As said,
specific inhibitors of complement might produce beneficial
effects, but also the possible caveats related to the inhibi-
tion of enzymatic cascade that is central to the normal
function of the immune system which a proper or ideal
therapy must seek to prevent [66]. The emergence of
structure-based drug design for the development of small
synthetic molecules for therapy holds promise, in spite of
formidable technical challenges.
Even though a lot of research has gone into finding the
use of complement in combating diseases, there is still the
need for more experimental exercises or studies to provide
more understanding into the mechanisms of complement
mediated damages. When a good insight is gained as to
how complement causes diseases, it will help provide a
good approach in designing the appropriate treatment that
will have a specific target to provide the needed cure. Also
identification of the component needed to be tackled or
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inhibited in a specific condition and targeting the actual site
to be inhibited in inflammation will be ideal to offer proper
treatment and avoid any side effects.
In contrast to inhibitors of the coagulation cascade, the
clinical application of complement inhibitors is still in its
infancy as robust data demonstrating clinical benefits are
still being produced. This might explain why so little
attention has been given by clinicians to this field. For the
time being, the good news is that some complement inhi-
bitors have already reached clinical phase I and II studies
as medical science strives to reach its goal in designing
therapies that target various steps in the immune response
[6, 25]. Table 1 shows some of the latest clinical studies of
complement inhibitors in human.
Current therapies of autoimmune diseases focus on
trying to alleviate symptoms, but fail to correct the fun-
damental immune defects that lead to the pathology high-
lighting the reason why the clinical management of
autoimmune diseases has been such a difficult task [24]. To
this end, new approaches such as therapeutic agents that
inhibit complement activation and prevent autoimmune
disease must receive the greatest attention [25]. It is our
opinion that when the best of the inhibitors being looked at
is well purified and passed through all the clinical trials to
show the highest capability of blocking complement
components from initiating the activation cascade, such an
inhibitor may be of a great benefit in the prevention and
treatment of autoimmune diseases.
Complement is believed to play a major role in host
defence against infection, but can cause damage to the host
system as well [1]. It is this damage that leads to it playing
a role in human diseases. In general, complement causes
damage by three mechanisms [4]. For certain targets,
interaction of the complement proteins with the target cell
or microorganism causes direct lysis of that microorganism
or cell [82]. In a second series of reactions, complement
proteins deposited on cells or microorganisms interact with
a series of specific receptors on phagocytes that aid in the
phagocytic process, thus removing the pathologic cell or
microorganism from the body [82].
Table 1 A table presenting some latest clinical studies of complement inhibitors in human
No. Clinical study References
1 Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal
meningitis: a randomized controlled trail
[104]
2 Atypical haemolytic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian
compassionate access cohort
[105]
3 Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule [106]
4 Complement inhibition for paroxysmal nocturnal hemoglobinuria: where we stand and where we are going [107]
5 Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid [108]
6 Expanding role of therapeutic antibodies [109]
7 A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models [110]
8 Current and future pharmacologic complement inhibitors [111]
9 Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion [112]
10 Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention [113]
11 Dissecting complement blockade for clinic use [114]
12 Complement therapy in atypical haemolytic uraemic syndrome (aHUS) [115]
13 Paroxysmal nocturnal haemoglobinuria and the age of therapeutic complement inhibition [116]
14 Complement inhibitors in phase 1 and 2 clinical studies for immunological disorders [117]
15 Inhibition of complement activation (eculizumab) in Guillain–Barre syndrome study [118]
16 An open label clinical trial of complement inhibition in multifocal motor neuropathy [119]
17 Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after
rituximab treatment in follicular non-Hodgkin
[120]
18 Complement activation and inhibition: a delicate balance [121]
19 Complement-mediated ischemia–reperfusion injury: lessons learned from animal and clinical studies [122]
20 Compstatin: a complement inhibitor on its way to clinical application [123]
21 Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of high
density lipoprotein (HDL)
[124]
22 Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal
hemoglobinuria
[5]
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Complement activation also leads to the generation of a
series of activation peptides that are capable of producing
inflammation [103]. In addition, complement is thought to
play a major role in the afferent limb of the immune
response, increasing the immunogenicity of antigens with
bound complement peptides [36]. It may also be important
in eliminating clones of lymphocytes involved in the
immune response to self antigens [64].
One of the diseases associated with complement acti-
vation is autoimmune disease [8]. Autoimmune diseases
represent a class of diseases which are often difficult to
treat effectively [9]. Although there are a number of drugs
which exist to treat them, none are adequate to control or
inhibit complement activation which is thought to trigger
the disease [10, 11]. The inhibition of complement may be
very important in a variety of these diseases because as the
complement system becomes active, there may be
destruction and removal of cells and substances, which
may be detrimental to the individual [32]. It is useful,
therefore, to have substances which can be administered to
patients to prevent active complement activation.
Many complement inhibitory substances have been
considered as therapeutic agents in helping to avert com-
plement-mediated damage leading to autoimmune disease.
Among the substances mentioned include CI- inhibitor,
recombinant proteins such as soluble CR1, C4BP, Factor
H, Factor I, DAF, MCP, CD59, antibodies comprising
Anti-MBL, -Factor D, -Properdin, -C5, C5a and C5b-9 and
finally small molecule inhibitors such as CI-binding pep-
tide and compstatin [64, 70, 90, 91].
The mode of administration, clearance and long-term
treatment, targeted organ or cells and potential side effects
of the substances if available have been considered to
ensure that qualified ones have been subjected to all kinds
of tests during trial and if their efficacy is proven, then they
can be used therapeutically for treatment of autoimmune
disease targeting complement activation [25, 38].
Conclusion
In the future as more and new complement inhibitors are
being discovered, there is the possibility that a better
inhibitor of complement activation will be found which
will help provide a formidable treatment for autoimmune
disease. Compared with conventional drugs, it is our
opinion that the use of complement inhibitors will be the
best option for treatment of autoimmune diseases based on
the advantages of the inhibitors outlined above.
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